Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | MEP1B | Q16820 | 8/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
| ▸ | MEP1A | Q16819 | 3/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630981 | 0.86 | FOLH1 (0.59) | MEN1KMT2AMEP1BFOLH1MEP1A | |
| SCHEMBL168738 | 0.86 | FOLH1 (0.59) | MEN1KMT2AMEP1BFOLH1MEP1A | |
| Hydrochloric Acid SCHEMBL15067497 | 0.84 | FOLH1 (0.58) | MEN1KMT2AMEP1BFOLH1MEP1A | |
| Hydrochloric Acid SCHEMBL29690742 | 0.84 | FOLH1 (0.58) | MEN1KMT2AMEP1BFOLH1MEP1A | |
| SCHEMBL4835879 | 0.84 | LOXL2 (0.60) | MEN1KMT2AFOLH1NPC1RAB9A | |
| SCHEMBL20794226 | 0.84 | MEP1B (0.54) | MEN1KMT2AMEP1BFOLH1MEP1A | |
| SCHEMBL7083845 | 0.84 | MEN1 (0.56) | MEN1KMT2AAOC3NPC1RAB9A | |
| SCHEMBL13229125 | 0.83 | KMT2A (0.90) | MEN1KMT2AHSD17B1HSD17B2 | |
| SCHEMBL11811255 | 0.82 | MEP1B (0.72) | MEN1KMT2AMEP1BFOLH1MEP1A | |
| SCHEMBL12505623 | 0.82 | MEN1 (0.54) | MEN1KMT2AAOC3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255109-A1 | Non-peptide GnRH antagonists | VANTIA, LTD | 2008-10-16 | — | — | US | disclosed |
| US-7365065-B2 | Non-peptide GnRH antagonists | FERRING B.V. (NL) | 2008-04-29 | — | — | US | disclosed |
| US-20050222139-A1 | Non-peptide gnrh antagonists | FERRING B.V. (NL) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222139-A1 | Non-peptide gnrh antagonists | GNRHR, BRS3, FSHR | MEN1 1089/4885KMT2A 1763/4885MEP1B 2212/4885 |
| US-20080255109-A1 | Non-peptide GnRH antagonists | GNRHR, BRS3, FSHR | MEN1 1037/4885KMT2A 1744/4885MEP1B 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.